​PIPC appreciates the administration’s goals to lower health costs for patients. PIPC remains concerned that the latest proposals to advance a Most Favored Nation pricing model for drugs will, in effect, import the worst of foreign health systems – their reliance on discriminatory value assessments. Stories from outside the U.S., like that of the Williams’ family, illustrate why quality-adjusted life years (QALYs) have no place in U.S. policy. Patients do not have the luxury of time.

In this week's edition...
 
— The Well News (Opinion): Most Favored Nation Drug Pricing Fails Patients and their Caregivers. View the opinion here.
— PIPC Data Mine Blog: Why Patients Shouldn’t Bear Individual Harms for Better Population Averages. View the new PIPC Data Mine Blog here.
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— PIPC Chairman Coelho Testifies to Oregon Department of Consumer and Business Services. View Chairman Coelho’s testimony here. View the testimony from Disability Rights Oregon here. Learn more about the hearing here.
— White House Issues RFI on Scientific Research & AI. See details below.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.

​The recent draft Health Technology Assessment (HTA) methods report released by the Health Economics Methods Advisory group makes it crystal clear – policy grounded in conventional HTA methods (like the QALY) are willing to harm the individual for the sake of the formula-derived average. 

PIPC shared the following statement highlighting its appreciation for the Trump Administration’s goal of lowering health care costs for patients awhile sharing continued concerns over the subjectivity and lack of transparency in the process for selecting a Maximum Fair Price (MFP), limited consideration of patient perspectives, and potential for continued reliance on value assessments conducted by the Institute for Clinical and Economic Review. 

In this week's edition...
 
— PIPC Responds to Medicare Negotiation Program’s Prices. View PIPC’s complete statement here. 
— White House Issues RFI on Scientific Research & AI. See details below.
— Oregon Invites ICER to Hearing on Pricing Despite Statewide QALY Ban. More information is available here.
— Draft HEMA Report: USC Schaeffer Makes Case Against Accepting Individual Harms to Improve Population Averages. View USC Schaeffer’s response to the draft report here.
— PIPC Statement on GENEROUS Model, also known as “Most Favored Nation." View the statement here.
— Prasad and Makary Discuss Novel FDA Plausible Mechanism Pathway. Click here to read the NEJM publication.
— New PQA Patient Advisory Council Seeks Nominations. Individuals can submit their nominations via this form. Additional details are provided in a recent PQA blog.
— PCORI Discusses the Importance of Patient-Centered Comparative CER Research. Click here to read more.
— Reps. Cammack and Hern Introduce QALY Ban Bill. See details below.
— Opportunity: Sign an Open Letter Rejecting Use of QALYs and Similar Measures. See details below.
— Update on the Texas v. Kennedy Lawsuit. See details below.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.